Effect of Xiangsha Liujunzi Decoction Combined with XELOX Chemotherapy and Bevacizumab Targeting Therapy on Short-term Efficacy and Tumor Markers in Patients with Advanced Colon Cancer
Objective:To investigate the effect of Xiangsha Liujunzi Decoction combined with XELOX chemotherapy and Bevacizumab targeting therapy on the short-term efficacy and tumor markers in patients with advanced colon cancer.Method:A total of 105 patients with advanced colon cancer admitted to Nanping People's Hospital from January 2020 to October 2023 were selected as the study objects and randomly divided into observation group(n=54)and control group(n=51).The control group was treated with XELOX chemotherapy and Bevacizumab targeting therapy,and the observation group was treated with Xiangsha Liujunzi Decoction on the basis of the control group.The short-term efficacy,immune function,tumor markers[carbohydrate antigen 242(CA242),carbohydrate antigen 199(CA199),carcinoembryonic antigen(CEA)]levels and the occurrence of adverse reactions between the two groups were compared.Result:The objective response rate(ORR)and disease control rate(DCR)in the observation group were 51.85%and 68.52%,respectively,which were higher than 31.37%and 49.02%in the control group,the differences were statistically significant(P<0.05).After treatment,the levels of CD3+and CD4+in two groups were lower than those before treatment,and the level of CD8+were higher than those before treatment,but the levels of CD3+and CD4+in the observation group were higher than those in the control group,and the level of CD8+was lower than that in the control group,the differences were statistically significant(P<0.05).After treatment,the CA242,CA199 and CEA levels in two groups were lower than those before treatment,and those in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).The incidence of gastrointestinal reaction in the observation group was 37.04%,which was lower than 56.86%in the control group,the difference was statistically significant(P<0.05).There were no significant differences in the incidence of alopecia,anemia,peripheral nerve toxicity and liver and kidney function injury between two groups(P>0.05).Conclusion:Xiangsha Liujunzi Decoction combined with XELOX chemotherapy and Bevacizumab targeted therapy can improve the short-term efficacy of advanced colon cancer,effectively improve the immune function of body,reduce the expression level of tumor markers,and have good safety.
万方数据
维普
